Abstract
Follicular lymphoma(FL)is a kind of indolent Non-Hodgkin lymphoma(NHL), which stems from follicle germinal center. A lot of research reported the latest development about treatment of FL in the 56th American Society of Hematology(ASH)annual meeting. Effect of radiotherapy for patients at low stage was determined, while the outcomes of clinical trials in which monoclonal antibody(GA101)in combination with chemotherapy for the advanced stage FL were exciting. In rituximab era, relapsed/refractory FL patients who receive stem cell transplantation could acquire preferable remissions. Several novel drugs(inhibitor of BTK or PI3K)for relapsed/refractory FL played a role of guidepost with the progression of corresponding trials. Key words: Follicular lymphoma; Treatment progression; American Society of Hematology annual meeting
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
